Drug offers huge potential for endometriosis

May 30, 2014
E2MATE is a steroidal derivative, based upon the sex steroid oestrogen.

A recent clinical study on a drug designed at the University has confirmed its potential in targeting the gynaecological disease endometriosis.

The study entitled 'Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age' appeared in the journal Reproductive Sciences earlier this year.

Endometriosis is a benign disease which leads to and infertility. With an estimated 80 million sufferers worldwide, the disease is still poorly understood. The discovery of is critical as most treatments have unpleasant side effects and current therapies have proved inadequate.

E2MATE, also known as PGL2001, was first designed and chemically synthesised in the Medicinal Chemistry Group of our Department of Pharmacy & Pharmacology.

The scientific basis for these trials was founded on a paper published in 2008 by teams at the University and Imperial College, London on Irosustat – another drug originating from the University. The paper showed that the drug, which has reached widespread Phase II cancer trials, has potential for the treatment of .

Commenting on the developments Professor Potter, who was the lead on both the E2MATE and Irosustat projects, said: "The most rewarding thing for any Drug Discovery Group is to see a drug we have designed in the lab overcome the multitude of very difficult hurdles and finally be administered to humans.

"Only the tiniest fraction of all such development candidates ever makes it this far, even in the pharma industry, as they require multidisciplinary teamwork and a multi-million pound budget. I am very encouraged that both our underpinning scientific concepts and the actual itself could translate into clinical benefit for a real unmet need".

Explore further: Cancer drug developed at University of Bath begins trials

More information: "Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age." Reproductive Sciences 1933719114522526, first published on March 6, 2014 DOI: 10.1177/1933719114522526

Related Stories

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.